Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II JSKN033 in advanced non-small cell lung cancer
ChiCTR2500111317Phase 2Not yet recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Oct 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of JSKN033 in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Hunan Cancer Hospital. Primary endpoints: Safety: TEAEs, TRAEs, SAEs and other safety findings and Objective response rate (ORR). Planned start Oct 2025; status: not yet recruiting.
02
Drugs
JSKN033
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500111317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111317.